Lifecore Biomedical (LFCR) Q4 2024 earnings summary

Executive summary

• Fiscal 2024 revenue reached $128.3 million, up 24.2% year-over-year, driven by growth in both HA manufacturing and CDMO businesses.

• The company completed divestitures of food businesses, becoming a standalone CDMO and transitioning to a single reporting segment.

• Net income from continuing operations was $9.3 million, reversing a $64.2 million loss in the prior year, aided by a $39.5 million decrease in the fair value of debt derivative liability.

• Leadership implemented a reduction in force in July to align headcount with business needs, resulting in $4.7 million in annual savings.

• Strategic focus is on maximizing base business, advancing the development portfolio, and aggressively adding new programs.

Financial highlights

• Gross profit for 2024 increased 49.5% to $41.9 million, with gross margin rising to 32.6% from 27.1% year-over-year.

• Adjusted EBITDA rose 82.2% to $20.2 million, with margin up 5.1 percentage points to 15.8%, excluding $6.2 million in stock-based compensation.

• Q4 2024 revenue was $37.9 million, up 21.6% year-over-year; gross profit was $17.3 million, up 122%.

• Net term and revolver debt increased by $27.7 million to $175.2 million, mainly due to non-cash PIK interest and additional borrowings.

• Capital expenditures were $17.9 million, focused on new isolator fillers and process equipment.

Outlook and guidance

• Fiscal 2025 revenue guidance is $126.5–$130 million, implying flat growth (-1.4% to +1.4%) year-over-year.

• Adjusted EBITDA guidance for 2025 is $19–$21 million, with margin expected between 15.3%–16.2%, excluding $9.0–$10.0 million in stock-based compensation.

• Gross margins are expected to decline by 225–275 basis points due to mix shift and higher depreciation.

• Operating expenses (excluding restructuring and stock-based comp) are expected to decrease by 200–250 basis points.

• CapEx for 2025 is projected at $10–$14 million, with slightly negative free cash flow expected.